Intelligence Profile
Research Papers
Fezolinetant has been the focus of several studies looking into its safety and efficacy, particularly for treating hot flashes associated with menopause and prostate cancer therapy.
A real-world safety analysis using the FAERS database examined fezolinetant's safety profile, identifying potential adverse events (Naunyn-Schmiedeberg's archives of pharmacology, Aug 2026). Similarly, a study in "Obstetrics and Gynecology" highlighted hepatic adverse events noted in postmarketing surveillance (May 2026).
For menopausal symptom management, fezolinetant is a Neurokinin 3 receptor antagonist. The research in "Obstetrics and Gynecology Clinics of North America" (Sep 2026) discusses its effectiveness, pointing to promising results, whereas another study detailed its usage in prostate cancer patients under androgen deprivation therapy ("The Prostate," Aug 2026).
A Japanese phase II study, STARLIGHT, showed positive patient-reported outcomes for menopausal vasomotor symptoms (Climacteric, May 2026). Additionally, the ongoing phase III trial (NCT06440967) aims to confirm its benefits for women with breast cancer experiencing hot flashes due to hormone therapy.
Completed phase I trials evaluated fezolinetant's pharmacokinetics and bioequivalence in healthy participants, showcasing safe profiles (NCT04793204, NCT04277624).
Fezolinetant has shown potential in symptom management for various conditions, but ongoing and future studies will further clarify its long-term safety and efficacy.
Disclaimer: This summary is for informational purposes only and is not a substitute for professional medical advice. Always consult a healthcare provider for medical decisions.